Theratechnologies, Inc. (TH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Theratechnologies, Inc. (TH)
Company Performance

Current Price

as of Oct 16, 2024

$1.28

P/E Ratio

N/A

Market Cap

$58.72M

Description

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Metrics

Overview

  • HQMontréal, QC
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerTH
  • Price$1.276255+0.69%

Trading Information

  • Market Cap$58.72M
  • Float78.93%
  • Average Daily Volume (1m)34,014
  • Average Daily Volume (3m)33,658
  • EPS-$0.13

Company

  • Revenue$114.83M
  • Rev Growth (1yr)11.31%
  • Net Income$4.23M
  • Gross Margin78.40%
  • EBITDA Margin27.39%
  • EBITDA$8.48M
  • EV$110.99M
  • EV/Revenue0.97
  • P/EN/A
  • P/S0.76
  • P/BN/A
Documents
Factset
Factset Business Description
Factset Street Account
Theratechnologies provides operational update; to cut up to 25 positions, record related restructuring charge (C$1.93, 0.00) (2023-10-24T11:11:49Z)
Theratechnologies announces results from Trogarzo (ibalizumab-uiyk) intramuscular administration study (C$2.48, 0.00) (2023-10-13T11:12:02Z)
Theratechnologies announces proposed public offering of common shares and concurrent private placement (C$1.71, 0.00) (2023-10-25T21:07:08Z)
Theratechnologies announces pricing of $25M public offering through Cantor Fitzgerald and concurrent private placement (C$1.71, 0.00) (2023-10-26T12:06:51Z)
Theratechnologies announces presentation of data on tesamorelin's reduction of visceral adipose tissue and liver fat in people with HIV on INSTIs at ID Week (C$2.48, 0.00) (2023-10-13T11:50:36Z)
Theratechnologies announces dosing of first patient in updated clinical trial of Sudocetaxel Zendusortide in advanced ovarian cancer (C$2.45, 0.00) (2023-10-12T11:32:31Z)